IRIDEX (IRIX) Q3 2026 Earnings Call Transcript

Source Motley_fool
Logo of jester cap with thought bubble.

Image source: The Motley Fool.

DATE

Tuesday, Nov. 17, 2026

CALL PARTICIPANTS

  • Chief Executive Officer - Patrick Mercer
  • Chief Financial Officer - Romeo Dizon
  • Investor Relations - Philip Taylor

TAKEAWAYS

  • Total Revenue -- $10.2 million, declining 19% due to international retina challenges and lower probe orders.
  • Retina Product Revenue -- $5.1 million, compared to $6.7 million last year, reflecting order timing and regulatory delays in international markets.
  • Cyclo G6 Revenue -- $3.2 million, decreasing from $3.5 million as international distributors reduced inventory purchased earlier in the year.
  • Global G6 Probe Volume -- 11,900 units, down from 14,900 units driven by international distributor ordering patterns.
  • Global G6 System Placements -- 28 systems, compared to 30 in the prior year period.
  • Gross Margin -- 42.4%, improving from 32.1% due to pricing discipline and the absence of a prior year inventory charge.
  • Pro Forma Gross Margin -- 38.7%, representing a 370 basis point increase when excluding a $800,000 inventory write-off in 2025.
  • Operating Expenses -- $5.5 million, remaining relatively flat compared to $5.4 million in the prior year quarter.
  • Net Loss -- $1.4 million, or $0.08 per share, improving from a net loss of $1.6 million in the third quarter of 2025.
  • Adjusted EBITDA Loss -- $0.6 million, increasing from a loss of $0.1 million in the prior year period.
  • Cash Balance -- $3.7 million, down from $4.7 million at the end of the second quarter.
  • Inventory Growth -- $1.6 million increase, driven by safety stock built to support distributors during the manufacturing relocation.
  • Full-Year Revenue Guidance -- $46 million to $48 million, lowered from the previous range of $51 million to $53 million.
  • Adjusted Operating Expense Guidance -- $19 million to $19.5 million, held consistent with previous expectations for the full year.
  • Annualized Rent Savings -- $600,000, resulting from the completed manufacturing relocation from Mountain View to San Jose.
  • U.S. PASCAL Sales -- 50% year-over-year growth, reflecting strong domestic interest in next-generation platforms.
  • U.S. G6 Probe Volume -- 6,900 units, remaining stable compared to the prior year period.
  • U.S. G6 System Placements -- 8 systems, up from 7 systems in the prior year period.
  • Deferred Japan Shipment -- $300,000, expected to realize in the fourth quarter after partner inventory builds ahead of the manufacturing move.
  • China Order Activity -- $400,000 year-to-date, down from $4 million in the prior year due to economic challenges and slow tender cycles.

Need a quote from a Motley Fool analyst? Email pr@fool.com

RISKS

  • Mercer stated, "results fell short of expectations," noting headwinds from international retina orders and ongoing regulatory delays.
  • Mercer warned that "economic challenges in China contributed to relatively stagnant order activity" and noted that registration delays in India continue to limit business.
  • Mercer indicated that medical retina results were impacted by "aggressive pricing pressure from larger competitors across Europe."

SUMMARY

Management reported segment revenue declines and updated guidance during the third quarter. IRIDEX (NASDAQ:IRIX) completed its manufacturing transition to San Jose and is pursuing a strategic review of its product portfolio to prioritize higher-margin revenue. The company reported a significant improvement in gross margins despite top-line headwinds, supported by sustained pricing discipline and a more favorable geographic mix. Management stated that the fourth quarter is expected to benefit from the release of remaining safety stock and the realization of deferred international shipments.

  • The company finished its manufacturing move on Oct. 5, which Mercer stated is "rightsized for the business we intend to run."
  • Management expects PASCAL MDR approval in the first half of 2027, which currently restricts sales in key markets including Germany and Austria.
  • The company is transitioning major products to third-party contract manufacturers, with completion targeted for 2027 to drive further margin expansion.
  • IRIDEX removed the Middle East from its revenue guidance earlier in the year and Mercer noted "recent developments in Saudi Arabia will continue to weigh on the activity in the region."
  • Dizon stated the company is "constantly still looking for reduction in operating expenses" through potential offshore transitions and product line streamlining.
  • The company completed TUV and BSI audits at the new San Jose facility and is waiting on final certificates to initiate international manufacturing.

INDUSTRY GLOSSARY

  • Cyclo G6: A laser system specifically designed for the treatment of glaucoma.
  • PASCAL: Pattern Scan Laser technology used for the treatment of retinal diseases.
  • MicroPulse: A laser delivery technology that uses short pulses to reduce tissue damage during treatment.
  • MDR: Medical Device Regulation, a stringent set of regulations governing the sale of medical devices in Europe.
  • LCD: Local Coverage Determination, decisions made by Medicare administrative contractors regarding whether a service is covered in a specific region.
  • EndoProbe: Consumable probes used by surgeons during vitrectomy procedures.
  • MIGS: Micro-Invasive Glaucoma Surgery, a category of surgical procedures for glaucoma treatment.

Full Conference Call Transcript

Operator: Ladies and gentlemen, thank you for standing by. My name is [ Abby ] and I will be your conference operator today. At this time, I would like to welcome everyone to the IRIDEX Third Quarter 2026 Earnings Conference Call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer session. [Operator Instructions] Thank you. And I would now like to turn the conference over to Trip Taylor, Investor Relations. You may begin.

Philip Taylor: Thanks, Operator, and good afternoon, everyone. Joining me on the call today from IRIDEX are Patrick Mercer, Chief Executive Officer, and Romeo Dizon, Chief Financial Officer. After the market closed today, IRIDEX released its financial results for the third quarter ended October 3rd, 2026. The release is available in the investor relations section of the company's website. Please note that today's discussion contains forward-looking statements within the meaning of the federal securities laws made under safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Forward-looking statements are any statements that do not relate strictly to historical facts, including statements about our strategy, goals, and priorities, our financial outlook, product development and regulatory matters, sales trends, and the markets we serve. These statements reflect management's current expectations and assumptions and are subject to significant risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied today. You should not place undue reliance on them. A discussion of these risks can be found in our most recent annual report on Form 10-K and quarterly reports on Form 10-Q on file with the SEC.

Except as required by law, IRIDEX undertakes no obligation to update or revise any forward-looking statements or financial projections, whether as a result of new information, future developments, or otherwise. During the call, we will also reference certain non-GAAP measures, including adjusted EBITDA and adjusted operating expenses. A reconciliation to the most directly comparable GAAP measure is included in today's press release. This call includes time-sensitive information that is accurate only as of the date of this live broadcast, November 17, 2026. With that, I'll turn the call over to Patrick.

Patrick Mercer: Thank you, Trip. Good afternoon, everyone, and thanks for being with us today. The recently completed quarter included some of the most important structural progress we have made recently as a company. Key among the many recent developments was the completion of our manufacturing relocation to our new headquarters in San Jose. Also noteworthy during the quarter was the significant improvement in gross margins, increasing 10 percentage points year-over-year and 8 percentage points sequentially. During the third quarter of 2025, we recorded a one-time write-off of approximately $0.8 million to cost of goods sold. Excluding this impact, pro forma gross margin was 38.7%, representing a solid 370 basis point improvement.

Together, these examples underscore the meaningful progress underway as we continue to retool and reposition our business, executing on our commitment to achieving sustainable profitability. While we continue to make meaningful progress on our longer-term strategic initiatives and operational improvements, we did encounter some headwinds in the third quarter, with revenue coming in below expectation. This was primarily driven by the timing of international retina orders, international distributors working through program inventory accumulated in anticipation of our manufacturing relocation, and ongoing regulatory delays. The third quarter results were disappointing, particularly given that they diverged from the positive trends we had observed earlier in the quarter.

Regardless of the contributing factors, our results fell short of expectations, and we have already begun taking decisive steps to address these headwinds. Our focus is clear. Every significant decision we make during the remainder of 2026 will be guided by a single objective: positioning IRIDEX to achieve greater profitability in 2027. I'll spend part of today outlining the actions we are taking and what the path forward looks like. In reviewing our forward-looking plans, let's start with operations. On October 5th, we finished moving our manufacturing operations from Mountain View to newer, more efficient, and significantly less expensive space in nearby San Jose.

The relocation was a complex project, and our team executed it while keeping our quality systems intact. Since completing the move, we have successfully completed both our TUV and BSI audits, and we are now waiting on the final audit reports and certificates to initiate manufacturing for international markets at our new location. We anticipate this relocation to deliver approximately $600,000 in annualized rent savings, with additional opportunities for manufacturing benefits expected as the new site is fully integrated into day-to-day operations. The new location gives us a facility that is rightsized for the business we intend to run.

As we outlined on our last call, a change in our manufacturing address requires re-registration in a number of international markets, and this creates short windows where we cannot ship under the new registration. To protect our distributors and their customers during those windows, we built safety stock utilizing the old address. That increased inventory is now starting to convert to revenue as international regulatory clearances are completed, and we continue to receive orders tied to upcoming blackout periods. This will become a tailwind for cash flows as working capital and inventory is steadily converted back into cash.

The combination of our inventory investment and the lower-than-expected third quarter revenue resulted in a cash use of roughly $1 million in the quarter. As safety stock converts to revenue and we collect the related receivables, we are driving towards a return to cash flow break-even. Glaucoma developments continue to be very encouraging, and the U.S. G6 product family revenue grew, supported by higher average selling prices and an increase in system placements. Internationally, probe orders were lower in the quarter as distributors worked through inventory they purchased in the first half, a pattern we flagged last quarter. In retina, U.S. PASCAL sales were the highlight of this segment, with year-over-year sales increasing by approximately 50%.

The rest of the retina business was challenged as a mix of deferred orders, regulatory constraints, and competitive pricing in specific international markets impacted results. I will now discuss each segment in further detail, starting with glaucoma. We saw several bright spots in U.S. glaucoma performance throughout the quarter, driven by the same 3 factors we highlighted last quarter: Medicare LCD tailwinds, targeted outreach through MedScout, and higher average selling prices. First, the Medicare LCD changes continue to improve the reimbursement environment and are encouraging physicians to consider MicroPulse TLT with G6 earlier in the treatment pathway. Our 2-year clinical follow-up data on MicroPulse TLT reinforces that shift.

Longer-term outcome data gives us a strong foundation for physician education and supports earlier use of the therapy, including in selected patients with mild to moderate disease. Second, our utilization platform continues to sharpen our commercial focus. MedScout helps our team target mid-utilization accounts and high-volume MIGS surgeons, where we see the clearest path to greater adoption. We also left the American Academy of Ophthalmology Conference with strong physician interest and active commercial conversations, which we expect to support adoption and utilization in the months ahead. Third, pricing remains a meaningful contributor. U.S. G6 probe ASP increased in 2025, and we have held that higher price level consistently throughout 2026.

We believe this reflects the value physicians place on MicroPulse therapy. G6 probe volume in the U.S. was 6,900 units, roughly in line with the prior year period, and we placed 8 G6 systems in the U.S. compared to 7 in the prior year quarter. Global G6 probe volume was approximately 11,900 units versus 14,900 in the prior year, with the declines coming primarily from international distributor ordering patterns. On systems, we placed 28 G6 systems in the quarter compared to 30 in the third quarter of 2025. Going deeper into details impacting our international glaucoma business, in Europe, Middle East, and Africa, results were shaped mainly by order timing.

Distributors accelerated G6 console and probe orders in the first and second quarters, which reduced third-quarter demand, and tighter inventory and purchasing controls at one of our larger distribution partners added to the effect. Supply constraints also delayed fulfillment of some G6 Probe Illuminate orders. In Germany and Austria, they continue to perform above plan as we recover business previously handled by our former distributor. New G6 console placements remain competitive, particularly against the A.R.C. FOX platform. In Asia, continued economic challenges in China contributed to relatively stagnant order activity in the third quarter.

In Japan, customers had placed significant orders in the second quarter ahead of our headquarters relocation and the associated business transition, resulting in lighter third-quarter purchasing as anticipated. Stocking orders in Korea and Malaysia ahead of the address change helped partially offset softer demand elsewhere in the region. Importantly, all outstanding EndoProbe backorders carried over from the second quarter for customers in China and Japan have now been fulfilled. In Latin America and Canada, G6 probe sales were stable. Orders from Peru and Chile offset lower purchasing in Brazil, where our distributor built inventory in the second quarter. Canada continues to deliver steady results following the commercial changes we made earlier this year.

Overall, the drivers of our glaucoma business remain intact: favorable reimbursement, a growing body of clinical evidence, more focused selling, and disciplined pricing. We remain focused on turning those advantages into steady probe volume growth and additional system placements. Now turning to retina. Our retina strategy continues to rest on 3 priorities: advancing the PASCAL upgrade cycle in the U.S., expanding PASCAL's international reach, and securing regulatory clearances for our next-generation platforms. We saw several bright spots domestically this quarter: U.S. PASCAL revenue increased approximately 50% year-over-year. Internationally, retina faced challenges concentrated in Asia and Europe. Turning first to Asia, in Japan, our partner deferred PASCAL shipments into the fourth quarter after building inventory ahead of our manufacturing relocation.

This deferral included 1 particular order of approximately $300,000 that we expect to ship in the fourth quarter. In China, economic weakness, regulatory challenges, and slow tender cycles continue to limit activity. In India, registration delays continue to limit our business to PASCAL sales only. In Europe, Middle East, and Africa, medical retina faced aggressive pricing pressure from larger competitors across Europe. Delays in PASCAL MDR certification also continued to restrict sales in key markets, including Germany and Austria. We continue to expect PASCAL MDR approval in the first half of 2027 and anticipate solid demand once completed. In Latin America and Canada, PASCAL sales have resumed after early market disruption, and we expect further improvement through year-end.

We anticipate some of the third-quarter retina impact, especially the Japan shipments, could be realized in the fourth quarter. Competitive pricing and regulatory timelines likely could take longer to work through, and we are planning accordingly. I will also want to acknowledge the Middle East. We removed the region from our guidance earlier in the year, and recent developments in Saudi Arabia will continue to weigh on the activity in the region. We will continue to serve customers in the region where we can, but we are not including recovery in our near-term outlook.

Looking at the remainder of the year, particularly to the fourth quarter, we expect financial results to benefit from the release of remaining safety stock, open international orders, and the deferred Japan PASCAL shipments, along with the typical year-end seasonal lift. At the same time, we expect these benefits to be offset by a continuation of headwinds discussed today, namely regulatory delays and competitive pricing pressure in retina, along with continued volatility in international ordering. Accordingly, we are updating our full-year 2026 revenue guidance to $46 million to $48 million, which continues to exclude revenue from the Middle East.

While this lowers our outlook for 2026, these same decisions are why we believe 2027 to be a more profitable year for IRIDEX. Romeo will provide more detail in a moment. Looking ahead to 2027, we expect to see, for the first time, the combined benefit of our cost-saving and margin initiatives. This includes the San Jose facility savings, the administrative function transfer, and the operating expense reductions we have made over the past 2 years. Beyond these activities, we are evaluating and planning additional meaningful operating expense reductions, which we expect to further lower our cost base in 2027. Second, we expect meaningful gross margin improvement as our major products move to third-party contract manufacturers.

We remain on track to complete that transition in 2027, and once our major products are contract manufactured, we expect gross margins to increase. Third, we are undertaking a comprehensive strategic review of our product portfolio and distribution model with the objective of sharpening our focus on higher-margin, more profitable revenue streams. As part of this effort, we are evaluating opportunities to streamline our product lines and reduce the overall size and complexity of our portfolio. A more focused product offering will not only improve operational efficiency, but also help reduce the ongoing costs and complexities associated with product obsolescence, inventory management and maintaining regulatory clearances across multiple markets.

In parallel, we are assessing distribution alternatives in select international markets to better align our commercial structure with our profitability objectives. In some regions, this may mean accepting lower revenue in exchange for stronger margins, a lower cost to serve, and more predictable ordering patterns. Ultimately, we expect these efforts to result in higher margins, a lower cost structure, and a more consistent cash flow-generating business model. With that, I'll turn the call over to Romeo to review the financials.

Romeo Dizon: Thank you, Patrick, and good afternoon, everyone. Total revenue for the third quarter of 2026 was $10.2 million, compared to $12.5 million in the third quarter of 2025. The third quarter decline came primarily from international retina and lower international probe orders, partially offset by growth in our U.S. glaucoma business. Retina product revenue was $5.1 million compared to $6.7 million in the prior year quarter. The decrease was driven by international markets where deferred shipments in Japan, continued weakness in China, registration delays in India, and competitive pricing and MDR regulatory timing in Europe restricted our revenues. Total product revenue for the Cyclo G6 product family was $3.2 million, compared to $3.5 million in the third quarter of 2025.

The decline is attributed to a decrease in international revenue, as distributors worked through inventory purchased earlier in the year, partially offset by higher U.S. probe ASPs and higher system revenue. Other revenue was $1.9 million compared to $2.2 million in the prior year period, mainly reflecting lower paid service revenue and the absence of royalty revenue in the current period. Gross profit for the third quarter was $4.3 million, translating to a gross margin of 42.4% of revenue, compared to $4.0 million, or 32.1%, in the third quarter of 2025. As Patrick indicated previously, in the third quarter of 2025, we recorded a one-time, non-recurring, non-cash $0.8 million charge to cost of goods sold due to an inventory write-down.

Excluding this write-down, gross margin as a percent of revenue would have been 38.7%, an improvement of approximately 370 basis points versus the prior year. The improvement reflects a more favorable geographic mix, along with sustained pricing discipline. We expect the move to third-party contract manufacturers to be the next significant driver of margin expansion as we move through 2027. Operating expenses for the third quarter were $5.5 million, essentially flat with $5.4 million in the prior year period. Net loss for the quarter was $1.4 million, or $0.08 per share, compared to a net loss of $1.6 million, or $0.09 per share, in the prior year period.

Non-GAAP adjusted EBITDA for the third quarter was a loss of $0.6 million compared to an adjusted EBITDA loss of $0.1 million in the third quarter of 2025. Moving to the balance sheet, we ended the quarter with cash and cash equivalents of $3.7 million as of October 3rd, 2026, compared to $4.7 million at the end of the second quarter. Net cash used in operating activities was $1.0 million in the quarter. The main driver was a $1.6 million increase in inventory as we built safety stock to support distributors through the registration blackout periods, along with lower revenue in the quarter. Moving forward, cash utilization should decrease significantly with stronger sales and reversal of the inventory stocking process.

Turning to guidance, for the full year 2026, we now expect revenue in the range of $46 million to $48 million. As a reminder, our outlook excludes revenues from the Middle East given the ongoing conflict in the region. We continue to expect adjusted operating expenses, which exclude depreciation, amortization, and stock-based compensation, to be in the range of $19 million to $19.5 million for the full year. We are not providing 2027 guidance today. Looking further out, we expect 2027 to reflect the full year benefit of our operating expense reductions, headquarters relocation, and the progressive move of products to contract manufacturers, resulting in a more profitable IRIDEX.

With that, I'll turn the call back to Patrick for closing remarks.

Patrick Mercer: Thanks, Romeo. The foundation for next year is strong. Our manufacturing relocation is complete and delivering the cost savings we anticipated, with more to come as the site is fully integrated. Gross margin improved meaningfully from the second quarter, and the safety stock we built is now becoming revenue-generating. Our glaucoma franchise continues to show its strength with year-to-date probe volume growth, higher U.S. pricing, and new 2-year MicroPulse TLT data that adds to our confidence in the therapy's long-term role. For the rest of 2026, our priorities are clear: complete our international clearances, continue advancing our contract manufacturing transition, and return to cash flow break-even.

We expect to enter 2027 as a more efficient IRIDEX with better margins, a lower cost base, generating operating profits, and a business model built to generate cash. Thank you for your continued support of IRIDEX. We look forward to updating you on our progress next quarter. Operator, please open the line for questions.

Operator: [Operator Instructions] And our first question comes from the line of Scott Henry with AGP. Your line is open.

Scott Henry: A lot to talk about. I'll try to take a higher-level, bigger-picture approach, but I do have a couple questions. Starting with retina, we've seen double-digit declines year-over-year for the last 3 quarters, and it looks like Q4 will be -- based on your guidance, it appears it will probably be close to double digits if not a double-digit decline. How do you think about -- and granted there's some moving parts impacting this year. But how do you think about the organic growth for that segment?

I think we were hoping we would be single digits or higher if it was gaining share, but how do you think about the category and I guess, that would likely play out in 2027 as well?

Patrick Mercer: Scott, and thank you for your question. You know, we've had this year -- this quarter in particular was a challenge for us. Even going into Q4 we see weakness in China. For example, last year we had $4 million in orders from China. This year we're up to -- we have about $400,000 from China. That's really been -- that's really hit us hard. We'd like to have had that $3.6 million. Japan, we've had a lot of volatility due to our blackout periods and working with the distributors to get those orders placed. Some have been cautious, some have wanted to wait.

For example, Japan placed a stocking order in Q2, so they didn't place any orders in Q3. We're seeing rising energy costs from the Iran war, which has affected our business in other regions outside the Middle East, particularly Asia and Europe. We are -- we're working through the headwinds as far as the regulatory delays and some of the competitive pricing. We are taking -- you talked about how we see '27; we are taking a strategic review of our product lines as we discussed in the script, mainly aimed at creating more profitable revenue streams for us. We're not going to sell in regions that aren't profitable anymore.

We're not going to go to countries that aren't profitable, and we're not going to put product lines forward that aren't profitable. So that's our 2027 plan. We're going to look at reducing -- continuing to reduce our OpEx, but really focusing on profitable segments of our business. And that's really what's going to help us overcome these things. We still believe in glaucoma. Glaucoma growth is really strong. So...

Scott Henry: Yes. I don't want to -- let's finish this line of questioning, if I can. Do you think you're gaining share in the markets you're in? Or do you think -- I mean, the numbers would suggest you're not, but I wanted to hear what you think.

Patrick Mercer: In the U.S. we certainly are. We grew the IP, which is our flagship product, by 50%. The OUS has been challenged by the issues I talked about previously. But in the U.S., we certainly are with our PASCAL system.

Scott Henry: And just for clarification, because I did see the breakout by geographic segment in the 10-Q, I understand the issue in China and Japan. In Europe, when you speak of regulatory delays, I mean, you're already in those markets. Are they taking products off the market, which would be negatively impacting you? Or -- because I feel like if you're being delayed on new products, you would still have your base business, but it seems like you're losing business. Could you just explain where the regulatory delays are impacting you?

Patrick Mercer: Yes, the regulatory delays, they're -- our new PASCAL product is our IP product, IRIDEX PASCAL, and that product has a lot more feature sets than our existing PASCAL. You are correct, we are selling the existing PASCAL in Europe today; however, a lot of those distributors know that the new IP product is going to be getting approved. So they're waiting to place orders for those products. So that's been the challenge. We've submitted everything to the notified bodies to get the MDR approval. We've had our BSI audits complete, our TUV audit. We are now just waiting for those approvals, which we hope will come in Q1. But yes, you're correct, we are selling in those markets.

However, a lot of the distributors have told us they're waiting to get approval before placing new orders for the new product.

Scott Henry: Okay. That's helpful. And then on the G6 business, I mean, you can see the, kind of, a lump in probes, particularly in Q2, perhaps a little in Q1. How are you thinking about probes in Q4? I mean, do you think we're back to a steady state? Or do you expect more inventory burn in Q4?

Patrick Mercer: Q4 is generally our largest quarter for not only probe sales, but G6 systems. So I anticipate that our probe volume will increase -- the amount of probe sales will increase in the Q4.

Scott Henry: Okay, and I assume you're speaking sequentially? Or do you think they'll increase year-over-year?

Patrick Mercer: I believe they'll increase year-over-year, but certainly sequentially.

Scott Henry: Okay. Well, year-over-year would imply pretty good growth. How about on systems? Do you think that -- I mean, that would increase sequentially and year-over-year? Last year was particularly good for Q4, and I think it was 44 systems.

Patrick Mercer: We still believe that's the case. Nothing's changed as far -- certainly over this quarter it will increase, but year-over-year we anticipate it will increase also. All the things that we've discussed previously with the LCD and [ we ] treated more moderate patients early in the continuum of care. We've been holding -- we didn't get a lot of orders in G6 systems for Q3 from OUS, so we expect those numbers to turn around.

Scott Henry: Okay, I -- your guidance would imply, I believe, an $11.5 million to $13.5 million revenue for Q4. Do you think that would be adjusted EBITDA positive for operations based on what we're seeing?

Romeo Dizon: Scott, this is Romeo. Thanks for the question. For the quarter, yes, if we reach the higher end of that revenue range, we will be, but not for the full year because of the prior 3-quarter losses that we've incurred.

Scott Henry: Yes, of course, Romeo. And then, final question, if you start to rationalize sales towards profitable sales, which, unless you're going to grow your way into profit, makes sense, that would imply that we would see gross margins increase or at least net margins because the losses are going to either come -- either going to add to gross margin or come out of expenses. What would you -- where would you expect that to show up? Because one of those metrics should improve, and in, sort of, what magnitude should we expect in 2027 for that improvement, just general terms?

Romeo Dizon: We expect it to come from both increases in margins as well a reduction in operating expenses. As you know, we've moved into the facilities already back in October, and we're starting to -- we've got -- we're 6-month free rent, and our rent's a lot lower. So a lot of that -- more than half of that, is allocated to cost of sales. So that'll lead to further expansion in the margins. And given the strategic product portfolio, like Patrick indicated earlier, we're going to start -- we're going to stop selling low margins and just focus on the profit. So that will add to that.

And we are also constantly still looking for reduction in operating expenses, such as perhaps moving some more things overseas or what have you. So that's always in the play.

Patrick Mercer: Thanks, Scott. Thanks, Romeo. Now I'll turn the call back over to the operator.

Operator: Thank you. And that actually concludes our question-and-answer session. So I would like to turn the conference back over to Mr. Patrick Mercer for any closing remarks.

Patrick Mercer: I want to thank everybody for joining us today, and we look forward to updating you on IRIDEX in the future. Thank you.

Operator: Ladies and gentlemen, this concludes today's call. We thank you for your participation, and you may now disconnect.

Should you buy stock in Iridex right now?

Before you buy stock in Iridex, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Iridex wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $321,850!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $955,232!*

Now, it’s worth noting Stock Advisor’s total average return is 793% — a market-crushing outperformance compared to 203% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

See the 10 stocks »

*Stock Advisor returns as of November 18, 2026.

This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. Parts of this article were created using Large Language Models (LLMs) based on The Motley Fool's insights and investing approach. It has been reviewed by our AI quality control systems. Since LLMs cannot (currently) own stocks, it has no positions in any of the stocks mentioned. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability.

The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Disclaimer: For information purposes only. Past performance is not indicative of future results.
placeholder
Market News Today Australia: VIX Jumps Nearly 19%, Gold Hits One-Year Low and Nasdaq 100 FallsNasdaq 100 falls 2.67%, gold hits a one-year low and WTI settles at US$85.72. See what Australian traders are watching ahead of Nvidia earnings.
Author  Mitrade Team
Yesterday 02: 29
Nasdaq 100 falls 2.67%, gold hits a one-year low and WTI settles at US$85.72. See what Australian traders are watching ahead of Nvidia earnings.
placeholder
Stocks, Gold, and Asia Bleed $2.2 Trillion: Top 5 Factors That Triggered the CrashGlobal markets lost roughly $2.2 trillion on November 16 as US stocks, precious metals, and Asian equities sold off together. Technology and AI-linked names led the decline.However, the rout did not s
Author  Beincrypto
Yesterday 02: 49
Global markets lost roughly $2.2 trillion on November 16 as US stocks, precious metals, and Asian equities sold off together. Technology and AI-linked names led the decline.However, the rout did not s
placeholder
Gold Price Today: Can XAU/USD Hold $3,870? | Mitrade AUGold rebounds near US$3,870 after hitting a one-year low. Explore XAU/USD support, Fed risks and what the outlook means for Australian traders.
Author  Mitrade Team
Yesterday 08: 50
Gold rebounds near US$3,870 after hitting a one-year low. Explore XAU/USD support, Fed risks and what the outlook means for Australian traders.
placeholder
Market News Today Australia: Gold Below US$3,900, US Stocks Fall as Nvidia Delivers Strong EarningsUS retail sales rise 0.2%, gold stays below US$3,900 and Nvidia beats earnings estimates. Explore the outlook for Australian CFD traders.
Author  Mitrade Team
13 hours ago
US retail sales rise 0.2%, gold stays below US$3,900 and Nvidia beats earnings estimates. Explore the outlook for Australian CFD traders.
placeholder
Gold Price Today: XAU/USD Breaks Below $3,800 | Mitrade AUGold falls below US$3,800 as Fed rate-hike expectations weigh. Explore XAU/USD levels, upcoming Fed minutes and the outlook for Australian traders.
Author  Mitrade Team
8 hours ago
Gold falls below US$3,800 as Fed rate-hike expectations weigh. Explore XAU/USD levels, upcoming Fed minutes and the outlook for Australian traders.
goTop
quote